Zentalis Pharmaceuticals, Inc. (ZNTL) is a Healthcare stock trading at $3.82 (as of 2026-08-21), with a market capitalization of $271.93M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Zentalis Pharmaceuticals develops small-molecule cancer therapies, with its lead candidate ZN-c3 in multiple clinical trials, and it currently has no product revenue disclosed in the provided latest-quarter figures.
The company’s profit model is primarily driven by whether ZN-c3 demonstrates clinical effectiveness and tolerability across its ongoing studies, because it is a clinical-stage biopharmaceutical company rather than a provider of already commercial products.
Business quality (Weak): Clear clinical focus on ZN-c3 with reported efficacy and safety metrics, but the company is still in development and shows a materially negative operating margin in the latest-quarter figures.
| Price | $3.82 |
| Market Cap | $271.93M |
| Price / Book | 1.89 |
| FCF Yield | -47.1% |
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -18.0% |
| FCF Growth (YoY) | -26.8% |
| Altman Z-Score | -4.38 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | 5AM Venture Management, LLC ($9.24M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Julie Eastland |
| Employees | 166 |
| Country | US |
| IPO Date | 2020-04-03 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.